{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:39:57Z","timestamp":1773293997775,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ajp.2020.102369","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T11:36:16Z","timestamp":1598873776000},"page":"102369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study"],"prefix":"10.1016","volume":"53","author":[{"given":"Tomihisa","family":"Niitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsugu","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitsugu","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goro","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Kanahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2020.102369_bib0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/acps.12742","article-title":"International trends in clozapine use: a study in 17 countries","volume":"136","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ajp.2020.102369_bib0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.schres.2014.09.020","article-title":"Use of very-high-dose olanzapine in treatment-resistant schizophrenia","volume":"159","author":"Batail","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment","volume":"5","author":"Chouinard","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.ajp.2020.102369_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.137.1.16","article-title":"Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics","volume":"137","author":"Chouinard","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0050","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.135.11.1409","article-title":"Neuroleptic-induced supersensitivity psychosis","volume":"135","author":"Chouinard","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0055","first-page":"891","article-title":"Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients","volume":"22","author":"Chouinard","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ajp.2020.102369_bib0060","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-198808001-00005","article-title":"A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases","volume":"8","author":"Chouinard","year":"1988","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.ajp.2020.102369_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia","volume":"24","author":"Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ajp.2020.102369_bib0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.ajp.2020.102369_bib0080","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1517\/14740338.4.4.731","article-title":"A review of clozapine safety","volume":"4","author":"Fitzsimons","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ajp.2020.102369_bib0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ajp.2020.102369_bib0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1471-2288-11-149","article-title":"Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review","volume":"11","author":"Garfield","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ajp.2020.102369_bib0095","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/archpsyc.61.3.310","article-title":"Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry","volume":"61","author":"Gueorguieva","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ajp.2020.102369_bib0105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pnpbp.2012.06.005","article-title":"Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein","volume":"39","author":"Inoue","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0110","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0b013e31828ea95c","article-title":"Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis","volume":"33","author":"Iyo","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.schres.2018.06.038","article-title":"Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis","volume":"202","author":"Kanahara","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2020.102369_bib0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2013.01.008","article-title":"Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis","volume":"145","author":"Kimura","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.schres.2014.02.022","article-title":"A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis","volume":"155","author":"Kimura","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0269881116655978","article-title":"Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up","volume":"30","author":"Kimura","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0145","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ajp.2020.102369_bib0150","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/npp.2010.50","article-title":"The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro","volume":"35","author":"McCormick","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ajp.2020.102369_bib0155","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/070674370104600308","article-title":"Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities","volume":"46","author":"McIntyre","year":"2001","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0160","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2174\/1389557515666150219125030","article-title":"Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders","volume":"15","author":"Mendonca Junior","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ajp.2020.102369_bib0165","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0269881117728428","article-title":"Dopamine supersensitivity psychosis in schizophrenia: concepts and implications in clinical practice","volume":"31","author":"Nakata","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0170","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/YIC.0000000000000160","article-title":"Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia","volume":"32","author":"Nakata","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0175","first-page":"859","article-title":"Usefulness of blonanserin in the add-on therapy and in the subsequent monotherapy for the treatment of auditory hallucinations in chironic treatment-resistant schizophrenia. (In Japanese)","volume":"17","author":"Nishimoto","year":"2014","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0180","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.30773\/pi.2018.09.06","article-title":"Differences in high dose antipsychotic prescriptions in patients with schizophrenia in asian countries\/areas: findings from the REAP-AP study","volume":"15","author":"Park","year":"2018","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.ajp.2020.102369_bib0185","doi-asserted-by":"crossref","DOI":"10.1177\/0004867418805559","article-title":"Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan","author":"Qiu","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0190","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.ajp.2020.102369_bib0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2013.10.003","article-title":"Is schizophrenia a dopamine supersensitivity psychotic reaction?","volume":"48","author":"Seeman","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-3956(97)00052-6","article-title":"The natural history and pathophysiology of treatment resistant schizophrenia","volume":"32","author":"Sheitman","year":"1998","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.ajp.2020.102369_bib0215","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2020.102369_bib0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajp.2016.08.014","article-title":"Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: a retrospective analysis","volume":"24","author":"Tachibana","year":"2016","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.ajp.2020.102369_bib0230","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/schbul\/sbr006","article-title":"Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis","volume":"38","author":"Tadokoro","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2020.102369_bib0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/JCP.0b013e3182825bce","article-title":"Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia","volume":"33","author":"Tateno","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2020.102369_bib0240","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.schres.2016.01.013","article-title":"Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: an analysis of multi-factors predicting long-term prognosis","volume":"170","author":"Yamanaka","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2020.102369_bib0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1139\/jpn.0552","article-title":"Augmentation of olanzapine in treatment-resistant schizophrenia","volume":"30","author":"Zink","year":"2005","journal-title":"J. Psychiatry Neurosci."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201820304822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201820304822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:36:07Z","timestamp":1761755767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201820304822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":49,"alternative-id":["S1876201820304822"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2020.102369","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2020.102369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102369"}}